Exploring Easily Accessible Neurophysiological Biomarkers for Predicting Alzheimer's Disease Progression: a Systematic Review

Overview

Journal Alzheimers Res Ther

Date 2024 Nov 4

PMID 39497149

Authors

Matteo Costanzo

Carolina Cutrona

Giorgio Leodori

Leonardo Malimpensa

Fabrizia DAntonio

Antonella Conte

Daniele Belvisi

Affiliations

Soon will be listed here.

Abstract

Alzheimer disease (AD) remains a significant global health concern. The progression from preclinical stages to overt dementia has become a crucial point of interest for researchers. This paper reviews the potential of neurophysiological biomarkers in predicting AD progression, based on a systematic literature search following PRISMA guidelines, including 55 studies. EEG-based techniques have been predominantly employed, whereas TMS studies are less common. Among the investigated neurophysiological measures, spectral power measurements and event-related potentials-based measures, including P300 and N200 latencies, have emerged as the most consistent and reliable biomarkers for predicting the likelihood of conversion to AD. In addition, TMS-based indices of cortical excitability and synaptic plasticity have also shown potential in assessing the risk of conversion to AD. However, concerns persist regarding the methodological discrepancies among studies, the accuracy of these neurophysiological measures in comparison to established AD biomarkers, and their immediate clinical applicability. Further research is needed to validate the predictive capabilities of EEG and TMS measures. Advancements in this area could lead to cost-effective, reliable biomarkers, enhancing diagnostic processes and deepening our understanding of AD pathophysiology.

Citing Articles

Cortical excitability and the aging brain: toward a biomarker of cognitive resilience.

Palermo S, Di Fazio C, Scaliti E, Stanziano M, Nigri A, Tamietto M Front Psychol. 2025; 16:1542880.

PMID: 40040658 PMC: 11878273. DOI: 10.3389/fpsyg.2025.1542880.

Electrochemical Technology for the Detection of Tau Proteins as a Biomarker of Alzheimer's Disease in Blood.

Wang J, Lu X, He Y Biosensors (Basel). 2025; 15(2).

PMID: 39996987 PMC: 11853436. DOI: 10.3390/bios15020085.

References

Babiloni C, Frisoni G, Vecchio F, Lizio R, Pievani M, Cristina G . Stability of clinical condition in mild cognitive impairment is related to cortical sources of alpha rhythms: an electroencephalographic study. Hum Brain Mapp. 2010; 32(11):1916-31. PMC: 6869969. DOI: 10.1002/hbm.21157. View

Jackson C, Snyder P . Electroencephalography and event-related potentials as biomarkers of mild cognitive impairment and mild Alzheimer's disease. Alzheimers Dement. 2008; 4(1 Suppl 1):S137-43. DOI: 10.1016/j.jalz.2007.10.008. View

Joseph S, Knezevic D, Zomorrodi R, Blumberger D, Daskalakis Z, Mulsant B . Dorsolateral prefrontal cortex excitability abnormalities in Alzheimer's Dementia: Findings from transcranial magnetic stimulation and electroencephalography study. Int J Psychophysiol. 2021; 169:55-62. DOI: 10.1016/j.ijpsycho.2021.08.008. View

Poil S, de Haan W, van der Flier W, Mansvelder H, Scheltens P, Linkenkaer-Hansen K . Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage. Front Aging Neurosci. 2013; 5:58. PMC: 3789214. DOI: 10.3389/fnagi.2013.00058. View

Dubois B, Epelbaum S, Nyasse F, Bakardjian H, Gagliardi G, Uspenskaya O . Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurol. 2018; 17(4):335-346. DOI: 10.1016/S1474-4422(18)30029-2. View

Jessen F, Amariglio R, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G . A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014; 10(6):844-52. PMC: 4317324. DOI: 10.1016/j.jalz.2014.01.001. View

Stefan K, Kunesch E, Cohen L, Benecke R, Classen J . Induction of plasticity in the human motor cortex by paired associative stimulation. Brain. 2000; 123 Pt 3:572-84. DOI: 10.1093/brain/123.3.572. View

Goldsworthy M, Hordacre B, Ridding M . Minimum number of trials required for within- and between-session reliability of TMS measures of corticospinal excitability. Neuroscience. 2016; 320:205-9. DOI: 10.1016/j.neuroscience.2016.02.012. View

Muller-Schiffmann A, Herring A, Abdel-Hafiz L, Chepkova A, Schable S, Wedel D . Amyloid-β dimers in the absence of plaque pathology impair learning and synaptic plasticity. Brain. 2015; 139(Pt 2):509-25. DOI: 10.1093/brain/awv355. View

10.

Babiloni C, Frisoni G, Pievani M, Vecchio F, Lizio R, Buttiglione M . Hippocampal volume and cortical sources of EEG alpha rhythms in mild cognitive impairment and Alzheimer disease. Neuroimage. 2008; 44(1):123-35. DOI: 10.1016/j.neuroimage.2008.08.005. View

11.

Goodman M, Kumar S, Zomorrodi R, Ghazala Z, Cheam A, Barr M . Theta-Gamma Coupling and Working Memory in Alzheimer's Dementia and Mild Cognitive Impairment. Front Aging Neurosci. 2018; 10:101. PMC: 5911490. DOI: 10.3389/fnagi.2018.00101. View

12.

Rothwell J, Hallett M, Berardelli A, Eisen A, Rossini P, Paulus W . Magnetic stimulation: motor evoked potentials. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl. 1999; 52:97-103. View

13.

Luckhaus C, Grass-Kapanke B, Blaeser I, Ihl R, Supprian T, Winterer G . Quantitative EEG in progressing vs stable mild cognitive impairment (MCI): results of a 1-year follow-up study. Int J Geriatr Psychiatry. 2008; 23(11):1148-55. DOI: 10.1002/gps.2042. View

14.

Trebbastoni A, Pichiorri F, DAntonio F, Campanelli A, Onesti E, Ceccanti M . Altered Cortical Synaptic Plasticity in Response to 5-Hz Repetitive Transcranial Magnetic Stimulation as a New Electrophysiological Finding in Amnestic Mild Cognitive Impairment Converting to Alzheimer's Disease: Results from a 4-year Prospective.... Front Aging Neurosci. 2016; 7:253. PMC: 4709411. DOI: 10.3389/fnagi.2015.00253. View

15.

Vucic S, Kiernan M . Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease. Neurotherapeutics. 2016; 14(1):91-106. PMC: 5233629. DOI: 10.1007/s13311-016-0487-6. View

16.

Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M . EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain. 2008; 131(Pt 3):690-705. DOI: 10.1093/brain/awm322. View

17.

Marquez F, Yassa M . Neuroimaging Biomarkers for Alzheimer's Disease. Mol Neurodegener. 2019; 14(1):21. PMC: 6555939. DOI: 10.1186/s13024-019-0325-5. View

18.

Killiany R, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F . Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol. 2000; 47(4):430-9. View

19.

Babiloni C, Carducci F, Lizio R, Vecchio F, Baglieri A, Bernardini S . Resting state cortical electroencephalographic rhythms are related to gray matter volume in subjects with mild cognitive impairment and Alzheimer's disease. Hum Brain Mapp. 2012; 34(6):1427-46. PMC: 6869852. DOI: 10.1002/hbm.22005. View

20.

Thal D, Beach T, Zanette M, Heurling K, Chakrabarty A, Ismail A . [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology. Alzheimers Dement. 2015; 11(8):975-85. DOI: 10.1016/j.jalz.2015.05.018. View